用于心血管疾病的 microRNA 治疗学：机遇与障碍。
MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles.
机构信息
miRagen Therapeutics, 6200 Lookout Rd, Boulder, Colorado 80301, USA.
出版信息
Nat Rev Drug Discov. 2012 Nov;11(11):860-72. doi: 10.1038/nrd3864. Epub 2012 Oct 19.
Abstract
In recent years, prominent roles for microRNAs (miRNAs) have been uncovered in several cardiovascular disorders. The ability to therapeutically manipulate miRNA expression and function through systemic or local delivery of miRNA inhibitors, referred to as antimiRs, has triggered enthusiasm for miRNAs as novel therapeutic targets. Here, we focus on the pharmacokinetic and pharmacodynamic properties of current antimiR designs and their relevance to cardiovascular indications, and evaluate the opportunities and obstacles associated with this new therapeutic modality.
摘要
近年来，microRNAs（miRNAs）在几种心血管疾病中的重要作用已被揭示。通过全身或局部递送 miRNA 抑制剂（称为 antimiRs）来治疗性地操纵 miRNA 表达和功能的能力激发了人们对 miRNA 作为新型治疗靶点的热情。在这里，我们重点关注当前 antimiR 设计的药代动力学和药效学特性及其与心血管适应症的相关性，并评估这种新治疗模式的相关机会和障碍。
相似文献
1
MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles.用于心血管疾病的 microRNA 治疗学：机遇与障碍。
Nat Rev Drug Discov. 2012 Nov;11(11):860-72. doi: 10.1038/nrd3864. Epub 2012 Oct 19.
2
microRNAs in Cardiovascular Disease: Small Molecules but Big Roles.微小 RNA 与心血管疾病：小分子，大作用。
Curr Top Med Chem. 2019;19(21):1918-1947. doi: 10.2174/1568026619666190808160241.
3
MicroRNAs as Candidate Drug Targets for Cardiovascular Diseases.微小RNA作为心血管疾病的候选药物靶点
Curr Drug Targets. 2017;18(4):463-472. doi: 10.2174/1389450117666160301101221.
4
HDL and microRNA therapeutics in cardiovascular disease.高密度脂蛋白与微小RNA疗法在心血管疾病中的应用
Pharmacol Ther. 2016 Dec;168:43-52. doi: 10.1016/j.pharmthera.2016.09.001. Epub 2016 Sep 3.
5
Development of microRNA therapeutics is coming of age.微小RNA疗法正在走向成熟。
EMBO Mol Med. 2014 Jul;6(7):851-64. doi: 10.15252/emmm.201100899.
6
MicroRNA-based therapeutic approaches in the cardiovascular system.基于 microRNA 的心血管系统治疗方法。
Cardiovasc Ther. 2012 Feb;30(1):e9-e15. doi: 10.1111/j.1755-5922.2010.00220.x. Epub 2010 Oct 14.
7
Nanoparticle-complexed antimiRs for inhibiting tumor growth and metastasis in prostate carcinoma and melanoma.用于抑制前列腺癌和黑色素瘤肿瘤生长和转移的纳米颗粒复合抗微小RNA
J Nanobiotechnology. 2020 Nov 23;18(1):173. doi: 10.1186/s12951-020-00728-w.
8
microRNA therapeutics in cardiovascular disease models.心血管疾病模型中的 microRNA 治疗学。
Annu Rev Pharmacol Toxicol. 2014;54:185-203. doi: 10.1146/annurev-pharmtox-011613-135957. Epub 2013 Oct 2.
9
MicroRNAs: a novel class of potential therapeutic targets for cardiovascular diseases.微小 RNA：心血管疾病治疗靶点的新一类潜在候选物。
Acta Pharmacol Sin. 2010 Jan;31(1):1-9. doi: 10.1038/aps.2009.175. Epub 2009 Dec 7.
10
Therapeutic advances in MicroRNA targeting.MicroRNA 靶向治疗的进展。
J Cardiovasc Pharmacol. 2011 Jan;57(1):1-7. doi: 10.1097/FJC.0b013e3181f603d0.
引用本文的文献
1
Estradiol Downregulates MicroRNA-193a to Mediate Its Angiogenic Actions.雌二醇下调微小RNA-193a以介导其血管生成作用。
Cells. 2025 Jul 23;14(15):1134. doi: 10.3390/cells14151134.
2
Exploring the Role of Genetic and Genomic Factors in Therapeutic Response to Heart Failure: A Comprehensive Analytical Review.探索遗传和基因组因素在心力衰竭治疗反应中的作用：一项综合分析综述。
Genes (Basel). 2025 Jul 4;16(7):801. doi: 10.3390/genes16070801.
3
miRBench: novel benchmark datasets for microRNA binding site prediction that mitigate against prevalent microRNA frequency class bias.miRBench：用于微小RNA结合位点预测的新型基准数据集，可减轻普遍存在的微小RNA频率类别偏差。
Bioinformatics. 2025 Jul 1;41(Supplement_1):i542-i551. doi: 10.1093/bioinformatics/btaf233.
4
Aging and sinus node dysfunction: mechanisms and future directions.衰老与窦房结功能障碍：机制与未来方向
Clin Sci (Lond). 2025 Jun 11;139(11):577-93. doi: 10.1042/CS20231025.
5
MiR-19-loaded oxidative stress-relief microgels with immunomodulatory and regeneration functions to reduce cardiac remodeling after myocardial infarction.负载 miR-19 的氧化应激缓解微凝胶具有免疫调节和再生功能，可减轻心肌梗死后的心脏重塑。
Bioact Mater. 2025 Feb 13;48:43-54. doi: 10.1016/j.bioactmat.2025.02.004. eCollection 2025 Jun.
6
Exosomes and miRNAs in Cardiovascular Diseases and Transcatheter Pulmonary Valve Replacement: Advancements, Gaps and Perspectives.心血管疾病与经导管肺动脉瓣置换中的外泌体和微小RNA：进展、差距与展望
Int J Mol Sci. 2024 Dec 21;25(24):13686. doi: 10.3390/ijms252413686.
7
An Autocatalytic Platform Combining a Nonlinear Hybridization Chain Reaction and DNAzyme to Detect microRNA.一种结合非线性杂交链式反应和脱氧核酶用于检测微小RNA的自催化平台。
Bio Protoc. 2024 Dec 20;14(24):e5134. doi: 10.21769/BioProtoc.5134.
8
Enzyme-Responsive Nanoparachute for Targeted miRNA Delivery: A Protective Strategy Against Acute Liver and Kidney Injury.用于靶向递送微小RNA的酶响应性纳米降落伞：一种针对急性肝肾损伤的保护策略
Adv Sci (Weinh). 2025 Mar;12(10):e2411210. doi: 10.1002/advs.202411210. Epub 2024 Dec 24.
9
MicroRNAs and hypospadias: A systematic review.微小RNA与尿道下裂：一项系统综述
Med Int (Lond). 2024 Nov 18;5(1):7. doi: 10.3892/mi.2024.206. eCollection 2025 Jan-Feb.
10
State of the art and perspectives of gene therapy in heart failure. A scientific statement of the Heart Failure Association of the ESC, the ESC Council on Cardiovascular Genomics and the ESC Working Group on Myocardial & Pericardial Diseases.心力衰竭基因治疗的现状与展望。欧洲心脏病学会心力衰竭协会、欧洲心脏病学会心血管基因组学委员会及欧洲心脏病学会心肌与心包疾病工作组的科学声明。
Eur J Heart Fail. 2025 Jan;27(1):5-25. doi: 10.1002/ejhf.3516. Epub 2024 Nov 22.
本文引用的文献
1
MicroRNA profiling identifies microRNA-155 as an adverse mediator of cardiac injury and dysfunction during acute viral myocarditis.microRNA 谱分析鉴定出 microRNA-155 是急性病毒性心肌炎中心脏损伤和功能障碍的不利介质。
Circ Res. 2012 Aug 3;111(4):415-25. doi: 10.1161/CIRCRESAHA.112.267443. Epub 2012 Jun 19.
2
A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples.miR-145 在肺动脉高压中的作用：来自小鼠模型和患者样本的证据。
Circ Res. 2012 Jul 20;111(3):290-300. doi: 10.1161/CIRCRESAHA.112.267591. Epub 2012 Jun 19.
3
Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2.病毒介导的 miR-196a 传递通过沉默 CELF2 改善 SBMA 表型。
Nat Med. 2012 Jul;18(7):1136-41. doi: 10.1038/nm.2791.
4
A cardiac microRNA governs systemic energy homeostasis by regulation of MED13.一种心脏 microRNA 通过调节 MED13 来控制全身能量稳态。
Cell. 2012 Apr 27;149(3):671-83. doi: 10.1016/j.cell.2012.03.029.
5
MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship.MicroRNAs 及其靶标：识别、调控及新兴的相互关系
Nat Rev Genet. 2012 Mar 13;13(4):271-82. doi: 10.1038/nrg3162.
6
miR-29 inhibits bleomycin-induced pulmonary fibrosis in mice.miR-29 抑制博来霉素诱导的小鼠肺纤维化。
Mol Ther. 2012 Jun;20(6):1251-60. doi: 10.1038/mt.2012.36. Epub 2012 Mar 6.
7
Protective role of estrogen-induced miRNA-29 expression in carbon tetrachloride-induced mouse liver injury.雌激素诱导的 miRNA-29 表达在四氯化碳诱导的小鼠肝损伤中的保护作用。
J Biol Chem. 2012 Apr 27;287(18):14851-62. doi: 10.1074/jbc.M111.314922. Epub 2012 Mar 5.
8
MicroRNAs in vascular and metabolic disease.血管和代谢疾病中的 microRNAs。
Circ Res. 2012 Feb 3;110(3):508-22. doi: 10.1161/CIRCRESAHA.111.247445.
9
Developing microRNA therapeutics.开发 microRNA 疗法。
Circ Res. 2012 Feb 3;110(3):496-507. doi: 10.1161/CIRCRESAHA.111.247916.
10
Inhibition of microRNA-29b reduces murine abdominal aortic aneurysm development.抑制 microRNA-29b 可减少小鼠腹主动脉瘤的发展。
J Clin Invest. 2012 Feb;122(2):497-506. doi: 10.1172/JCI61598. Epub 2012 Jan 24.
Zotero 插件